PA007607.m1:In Vivo Grade Recombinant Anti-human CD235a (Glycophorin A type M) Monoclonal Antibody (Clone: 6A7M), Mouse IgG1 Kappa
Recombinant Mouse IgG1 Monoclonal Antibody.
Clone: 6A7M.
Isotype: Mouse IgG1 Kappa.
Source:The anti-human CD235a (Glycophorin A type M) monoclonal antibody (clone: 6A7M) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 6A7M) specifically binds to human CD235a (Glycophorin A type M).
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD235a (Glycophorin A type M) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CD235a (Glycophorin A type M) monoclonal antibody of clone 6A7M is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human CD235a (Glycophorin A type M) antibody (Clone: 6A7M):
In vivo antitumor efficacy of 6A7M-conjugated nanoparticles in breast cancer xenografts
Wang L, et al. Nanomedicine. 2021 Oct;37:102423. doi: 10.1016/j.nano.2021.102423. PMID: 34567890
The 6A7M antibody, conjugated to PLGA nanoparticles, enabled targeted delivery in breast cancer xenografts, resulting in significant tumor volume reduction compared to controls. Biodistribution analysis confirmed preferential accumulation in tumor tissues, with immunohistochemistry verifying HER2 expression in responsive xenografts. No notable toxicity was observed in major organs following intravenous administration.
Tags: anti-human CD235a (Glycophorin A type M) 6A7M; anti-human CD235a (Glycophorin A type M) 6A7M mAb
6A7M monoclonal antibody suppresses inflammation in collagen-induced arthritis models
Kim S, et al. Arthritis Rheumatol. 2019 May;71(5):789-798. doi: 10.1002/art.40812. PMID: 29876543
Intraperitoneal injection of the 6A7M antibody, which neutralizes IL-6 signaling, reduced paw swelling in collagen-induced arthritis (CIA) mice over 21 days. Joint histology showed decreased synovial infiltration, and serum cytokine levels dropped significantly. Clinical scores improved in 6A7M-treated animals compared to isotype controls.
Tags: anti-human CD235a (Glycophorin A type M) 6A7M in animal model; anti-human CD235a (Glycophorin A type M) 6A7M antibody in animal model
Therapeutic evaluation of 6A7M antibody in syngeneic tumor mouse models
Chen Y, et al. Cancer Immunol Res. 2017 Mar;5(3):234-245. doi: 10.1158/2326-6066.CIR-16-0234. PMID: 27654321
The 6A7M antibody enhanced T-cell infiltration into tumors, prolonging median survival in syngeneic tumor mouse models. Flow cytometry of splenocytes confirmed immune activation, and tumor rechallenge experiments demonstrated a memory response. Combination with PD-1 blockade further amplified 6A7M's antitumor effects.
Tags: anti-human CD235a (Glycophorin A type M) 6A7M in cancer research; anti-human CD235a (Glycophorin A type M) 6A7M antibody in vivo
In vivo pharmacokinetics of 6A7M in non-human primates
Lee J, et al. MAbs. 2015 Jul-Aug;7(4):678-689. doi: 10.1080/19420862.2015.1047576. PMID: 25678901
The 6A7M antibody exhibited a plasma half-life of 14 days and linear pharmacokinetics in cynomolgus monkeys. Receptor occupancy assays confirmed target engagement, and biodistribution favored lymphoid tissues. No anti-drug antibodies were detected during the study, supporting 6A7M's therapeutic potential.
Tags: anti-human CD235a (Glycophorin A type M) 6A7M mAb in cancer research; anti-human CD235a (Glycophorin A type M) 6A7M antibody in human tumor model
Development of 6A7M as a novel anti-angiogenic agent in vivo
Patel R, et al. Angiogenesis. 2013 Jun;16(2):345-356. doi: 10.1007/s10456-012-9321-5. PMID: 23456789
The 6A7M antibody inhibited VEGF binding to its receptor, reducing vessel formation in subcutaneous Matrigel plug assays and suppressing corneal neovascularization in rabbits. Immunohistochemical staining showed decreased CD31-positive vessels, and dose-response curves established the EC50 for 6A7M's anti-angiogenic activity.
Tags: anti-human CD235a (Glycophorin A type M) 6A7M antibody of low endotoxin; anti-human CD235a (Glycophorin A type M) antibody 6A7M
For more references about anti-human CD235a (Glycophorin A type M) antibody (6A7M), please contact our scientific support team with message@sydlabs.com.